JPMorgan Predicts 66%: In a recent development that has caught the attention of investors in the pharmaceutical sector, JPMorgan has initiated coverage on Travere Therapeutics with an overweight rating and a price target of $26. The financial giant’s bullish stance on the relatively unknown biotech company is based on its long-term growth potential. Travere Therapeutics is a San Diego-based biopharmaceutical company that focuses on identifying, … Continue reading JPMorgan Predicts 66% Rally for Little-Known Biotech Company, Travere Therapeutics